Drugs / SEP-4199
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03543410 | Jun 2018 → Apr 2020 | bipolar depression, major depressive disorder | Sumitomo Pharma America, Inc. | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT05227209 | Mar 2022 → Nov 2023 | bipolar depression | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05169710 | Dec 2021 → Oct 2023 | bipolar depression | Sumitomo Pharma America, Inc. | Terminated | Mixed Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEP-4199 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03543410 ↗ |
| Known as | amisulpride | “Consistent with increasing the certainty of MADRS ratings, subjects with a canonical symptom structure at baseline demonstrated greater effect sizes post-baseline in a phase 2...” PMID 39098761 ↗ Aug 2024 |
| Action | Inhibit | “5-HT7 receptor (5-HT7R) antagonism” PMID 33961287 ↗ Jun 2021 |